So cool to see our cofounder and CSO, @MRudnickiOHRI, featured in the Ottawa Citizen! A decade ago, Dr. Rudnicki made a groundbreaking discovery in Duchenne muscular dystrophy research that changed the understanding of the disease. Today, that breakthrough has paved the way for…

Satellos is thrilled to welcome Stephanie Brown to our Board of Directors! With over 30 years of biopharma industry experience and a proven track record in launching rare disease treatments, Stephanie's expertise will help propel our mission to deliver transformative therapies…

We are pleased to announce our Q3 2024 financial results as well as provide an update on clinical progress of SAT-3247, our investigational treatment for Duchenne muscular dystrophy (DMD). Our Phase 1 study for SAT-3247 is progressing smoothly, with no safety concerns reported in…

We were fortunate to hear from Elijah Stacy at the 2024 Family Forum. Elijah, a young man living with WDuchenne, shared his personal story and some incredible words of inspiration with our community. Watch now and share with your friends and family: bit.ly/3Yf5ZUX.

We will be presenting and participating in key investor conferences this November around the world. We look forward to discussing the advancement of our lead drug candidate, SAT-3247, into clinical trials and recent preclinical data in a canine model of #Duchenne…

What are the opportunities & challenges associated with financing companies, securing IP, & navigating Canada’s commercialization ecosystem to advance new regenerative medicine products and technologies? Satellos Co-founder and CEO @frank_satellos will be the keynote speaker at…

Join PPMD and @SatellosBio Wednesday 10/30 at 1 PM ET, as we explore SAT-3247, a new approach for the treatment of #Duchenne. Register now and submit questions in advance. parentprojectmd-org.zoom.us/webinar/regist…

When you're designing a drug for a patient population that is severely compromised or facing additional challenges, efficacy isn't the only consideration. The end goal is an easy to administer medication with a benign side effect profile that could fit well into a full regimen of…

We are thrilled to announce the upcoming presentation of data showing treatment of DMD canines with SAT-3247 improved measures of strength to near normal levels. Key highlights include: 🔹 Significant improvements in muscle morphology and regeneration across key muscle groups,…

🎙️ What better way to celebrate #InternationalPodcastDay than to discover some new listens? We recommend the @destroydisease podcast with @Elijahjstacy Our CEO @frank_satellos recently joined to talk about his leadership learnings as well as the science behind our lead program…

Around the world for Duchenne! It’s not just about raising awareness…it’s about building hope (and muscle!). For Duchenne Action Month and World Duchenne Awareness Day, Satellos was proud to attend and support organizations around the world who raise awareness for Duchenne…

We are pleased to announce that we’ve dosed our first participant in a Phase 1 clinical study of SAT-3247 – a small molecule drug candidate designed to promote skeletal muscle regeneration for #Duchenne #musculardystrophy and other degenerative or injury conditions involving…

Satellos Co-founder and CEO @frank_satellos will be speaking at the @DefeatDuchenne Family Forum, a national education program specifically designed for families living with Duchenne muscular dystrophy. Frank will discuss the company’s lead drug candidate that is designed to…

We're excited to be heading to Australia to participate in the @SaveOurSons 2024 National Duchenne Conference. We will have a booth to share more about our lead drug candidate, SAT-3247, and our Phase 1 clinical trial. SAT-3247 is an oral small molecule drug being developed by…

We will be presenting and participating in key investor conferences this September in New York City. We will be discussing the additional preclinical data we’ve disclosed over the summer as well as the advancement of our lead drug candidate, SAT-3247, into clinical trials.…

The formation of Satellos Bioscience involved more than just finding a target and creating a new medicine. As co-founder and CEO @frank_satellos tells #DestroyDuchenne founder @Elijahjstacy, it was about challenging scientific convention and figuring out how to do something no…

Our CEO @frank_satellos spoke with @TrialsArena about the details of our upcoming #clinicaltrials for SAT-3247, which we are developing as a novel #smallmolecule medicine for #Duchenne #musculardystrophy. Read the article here: clinicaltrialsarena.com/news/satellos-… #raredisease #rarediseases…

Today, we are excited to announce the acceptance of our regulatory filing that allows us to begin our Phase 1 clinical trial with SAT-3247. We look forward to beginning enrollment in the study and dosing our first participant. Read the release for more details:…

We are pleased to announce our Q2 2024 financial results as well as provide updated data from a canine model of #Duchenne #musculardystrophy. These data show further increased improvement in muscle force over baseline of 195% at four months after oral treatment with SAT-3247. We…

We are pleased to announce today that Satellos has received Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the treatment of #Duchenne #musculardystrophy. SAT-3247 is a proprietary, oral small molecule drug being developed by Satellos as a novel treatment…